Loading viewer...
investor_presentation
Format: PDF investor_presentation
October 2016 equity research report on Tempur Sealy (TPX) analyzing the company's September 27 guidance revision that reduced FY2016 revenue and EBITDA targets. The analysis highlights improving EBITDA margins despite revenue pressure, potential Sealy goodwill impairment risks of $2.00-$4.50 per share, and strategic implications of the Steinhoff acquisition of Mattress Firm (TPX's largest customer at 25% of sales).
presentation
investor_presentation
69 Pages
Itaú Corpbanca
Zentalis Pharmaceuticals 2023 Corporate Presentation
investor_presentationinvestor_presentation
47 Pages
Zentalis Pharmaceuticals, Inc.
investor_presentation
Yamato Kogyo